Recently, the performance of X-ray computed tomography (CT) and magnetic resonance imaging (MRI) method has been greatly improved, particularly in terms of their spatial resolution and technology for reconstructing the acquired images. Nuclear medicine imaging has been considered to be the most sensitive approach for diagnosing bone disorders such as bone metastases due to its ability to enable the early detection of abnormalities, namely, visualization of lesion sites before anatomical changes. For a long time, Tc has the convenient physical characteristics [moderate half-life (6.01 h) for clinical use, a generator-produced radionuclide, and appropriate gamma ray energy for imaging] and imaging methods using conventional gamma cameras are simple. 
Recently, the performance of X-ray computed tomography (CT) and magnetic resonance imaging (MRI) method has been greatly improved, particularly in terms of their spatial resolution and technology for reconstructing the acquired images. Nuclear medicine imaging has been considered to be the most sensitive approach for diagnosing bone disorders such as bone metastases due to its ability to enable the early detection of abnormalities, namely, visualization of lesion sites before anatomical changes. For a long time, Tc has the convenient physical characteristics [moderate half-life (6.01 h) for clinical use, a generator-produced radionuclide, and appropriate gamma ray energy for imaging] and imaging methods using conventional gamma cameras are simple. Tc with bisphosphonate analogs having high affinity for bone since the phosphate groups in the bisphosphonate can be coordinated with calcium in hydroxyapatite crystals in bone.
The use of [ 18 F]NaF for bone imaging was initially reported by Blau et al. in 1962 6 and approved by the US Food and Drug Administration in 1972. [ 18 F]NaF accumulates at a high level in bone because of chemisorption with the exchange of fluoride anions with the hydroxyl groups in hydroxyapatite [Ca 10 (PO 4 ) 6 Tc-MDP single photon emission computed tomography (SPECT) imaging 7 , the problems of limited availability and the high cost of cyclotrons have remained unresolved.
In recent years, 68 Ga (T 1/2 = 68 min) has drawn substantial attention as a positron emission radionuclide for clinical PET because of its attractive radiophysical properties, such as reasonable half-life for clinical use; it has particularly been used as a generator-produced radionuclide. 68 Ga-PET does not require an on-site cyclotron because 68 Ga can be eluted from the generator on demand. Moreover, as the parent nuclide, 68 Ge (T 1/2 = 271 days) has a long half-life, a generator could be used for a long period. Therefore, the demand for 68 Ga-labeled compounds for the diagnosis of bone disorders, such as bone metastases, has increased. Some new . The acidic amino acid peptides (poly-glutamic and poly-aspartic acids) also have a high affinity for hydroxyapatite because side-chain carboxyl groups in the acidic amino acid peptides can be coordinated with calcium in hydroxyapatite, and could become carriers delivering drugs to bone [16] [17] [18] . Recently, 1,4,7,10-tetraa zacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has been used as a chelating site, and Ga-DOTA-conjugated aspartic acid peptides [Ga-DOTA-(L-Asp) n ], with varying peptide lengths (n = 2, 5, 8, 11, or 14) , have been developed and evaluated using the easy-to-handle radioisotope 67 Ga, which has a longer half-life (3.3 days), rather than 68 Ga 19 . 67 Ga-DOTA-(L-Asp) 11 and 67 Ga-DOTA-(L-Asp) 14 show high affinity for hydroxyapatite, high accumulation in bone, and rapid blood clearance in biodistribution experiments in normal mice. Accordingly, the bone/blood ratios of 67 Ga-DOTA-(L-Asp) 11 and 67 Ga-DOTA-(L-Asp) 14 are comparable to those of 99m Tc-HMDP and 67 Ga-DOTA-Bn-SCN-HBP (Fig. 1A) , a Ga-DOTA-conjugated bisphosphonate, which was developed and evaluated in our previous study 11 . In these Ga-DOTA-conjugated aspartic acid peptide compounds, L-aspartic acid is used as the only component of the peptides. However, the peptides composed of D-amino acids could be more stable in vivo than the peptides built with L-amino acids because they are not readily recognized by the peptidases 20 . Thus, in this study, 67 Ga-DOTA-(D-Asp) n (Fig. 1B) of varying peptide lengths (n = 2, 5, 8, 11, or 14) were synthesized and evaluated. Moreover, to compare the different acidic amino acids as components of the carrier, 67 Ga-DOTA-(L-Glu) 14 ( Fig. 1C) and 67 Ga-DOTA-(D-Glu) 14 ( Fig. 1D ) were synthesized and evaluated in vitro and in vivo. F]NaF, and 99m Tc-MDP showed high accumulation and retention of radioactivity in bone. 67 Ga-DOTA-(D-Asp) 5 showed moderate accumulation of radioactivity in bone; however, the level of radioactivity decreased 3 h after injection. 67 Ga-DOTA-(D-Asp) 2 caused subtle accumulation of radioactivity in bone. Although there was little radioactivity in other tissues at 3 h after the injection of 67 Ga
Tc-MDP, and [
18 F]NaF because of rapid excretion via the kidneys, the radioactivity in the kidneys after the injection of 67 Ga-DOTA-(L-Glu) 14 and 67 Ga-DOTA-(D-Glu) 14 was retained.
Urine Analyses. The results of urine analysis using RP-HPLC after injection of 67 Ga-DOTA-(L-Asp) 14 and 67 Ga-DOTA-(D-Asp) 14 showed that a part of these complexes metabolized to more hydrophilic complexes; some radioactivity was eluted earlier than the intact complex. The ratio of the intact complex after injection of 67 Ga-DOTA-(D-Asp) 14 (85.8 ± 17.4%) was significantly higher than that of 67 Ga-DOTA-(L-Asp) 14 (55.0 ± 13.9%).
Discussion
It has been shown that the bisphosphonate structure is very useful as a carrier of physiologically active molecules or compounds with medicinal properties. This is particularly true for bone lesions because of the high affinity of bisphosphonate for hydroxyapatite, which is plentiful in bone but not in soft tissues 21, 22 . Stable radiometal complex-conjugated bisphosphonate compounds have been designed as bone-seeking radiopharmaceuticals; they have been synthesized and evaluated for the diagnosis and therapy of bone metastases 11, [23] [24] [25] [26] [27] [28] [29] [30] . The available data show that bisphosphonate is an excellent carrier of radioisotopes to bone lesions. Our recent study has shown that L-aspartic acid peptides could also work as carriers of radioisotopes to bone lesions; L-aspartic acid peptides have high affinity for hydroxyapatite 19, 31 . Thus, we assumed that D-aspartic acid peptides might be even better carriers. They should have a similar degree of affinity for hydroxyapatite but higher stability in vivo than the L-aspartic acid compounds.
In the hydroxyapatite-binding assay, 67 Ga-DOTA-(D-Asp) n with a longer amino acid chain showed higher affinity for hydroxyapatite than the short-chain compounds. The binding patterns of 67 Ga-DOTA-(D-Asp) n were almost the same as those of 67 Ga-DOTA-(L-Asp) n
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. A previous study reported that the dissociation constants and the maximal binding rates of Fmoc-peptide compounds for hydroxyapatite show no significant differences among Fmoc-(L-Asp) n , Fmoc-(D-Asp) n , and Fmoc-(L-Glu) n (n = 2, 4, 6, 8, 10) 32 . This is consistent with the results of hydroxyapatite binding assay in our study. We found that aspartic acid peptides had the same degree of affinity for hydroxyapatite regardless of their optical isomeric form. Moreover, there were no differences between the affinities of aspartic acid peptides and glutamic acid peptides for hydroxyapatite.
In in vivo studies, it is known that the peptides that composed of D-amino acids are more stable than the L-amino acid peptides 20 . A study examining the Fmoc compounds reported that, after a single i.v. administration, the plasma concentration of Fmoc-(L-Asp) 6 decreased more rapidly than the concentration of Fmoc-(D-Asp) 6 . Degradation products did not appear in the plasma after the injection of Fmoc-(D-Asp) 6 , but Fmoc-(L-Asp) 4 and Fmoc-(L-Asp) 2 were detected in plasma after the injection of Fmoc-(L-Asp) 6 32 . Therefore, we had expected to 14 , and (D) Ga-DOTA-(D-Glu) 14 .
observe increased accumulation in bone after the injection of 67 Ga-DOTA-(D-Asp) n , caused by their superior in vivo stability. In urine analyses, 67 Ga-DOTA-(L-Asp) 14 metabolized to more hydrophilic complexes, which should be 67 Ga-DOTA conjugated with shorter aspartic acid peptides, because of the cleavage of an amide bond in the peptide. These compounds were diluted before the full-length compound during the RP-HPLC using an ODS column. This indicates that 67 Ga-DOTA-(D-Asp) 14 is more stable than 67 Ga-DOTA-(L-Asp) 14 . Since 67 Ga-DOTA conjugated with shorter aspartic acid peptides should show lower accumulation in bone than 67 Ga-DOTA conjugated with long aspartic acid peptides, we expected that 67 Ga-DOTA-(D-Asp) n , which has higher stability, would show higher accumulation in bone than 67 Ga-DOTA-(L-Asp) n . However, against our expectations, the accumulation of radioactivity in bone was comparable for 67 Ga-DOTA-(L-Asp) n and 67 Ga-DOTA-(D-Asp) n . Not only 67 Ga-DOTA-(D-Asp) n but also 67 Ga-DOTA-(L-Asp) n immediately accumulated in bone or was excreted into urine via the kidneys with little degradation; both molecule types showed extremely rapid clearance from the blood. There was no difference between the biodistributions of 67 Ga-DOTA-(L-Asp) n and 67 Ga-DOTA-(D-Asp) n . To compare the biodistributions of 67 Ga-DOTA-conjugated acidic amino acid peptides with the biodistributions of other typical bone-seeking compounds, biodistribution experiments of 99m Tc-MDP and [
18 F]NaF were , 67 Ga-DOTA-(L-Glu) 14 , and 67 Ga-DOTA-(D-Glu) 14 to hydroxyapatite beads. Data are shown as the mean ± SD for four samples. Ga-DOTA-(D-Asp) n (n = 11 or 14) should be useful in a clinical context. The 67 Ga-DOTA-conjugated L-glutamic acid peptide, 67 Ga-DOTA-(L-Glu) 14 , and the 67 Ga-DOTA-conjugated D-glutamic acid peptide, 67 Ga-DOTA-(D-Glu) 14 , also showed rapid clearance from the blood and high accumulation in bone, similarly to 67 Ga-DOTA-(L-Asp) 14 and 67 Ga-DOTA-(D-Asp) 14 . Generally, radiometal-labeled peptides tend to show a high accumulation of radioactivity in the kidneys. It has been reported that the accumulation of radioactivity in the kidneys after the injection of 111 In-labeled peptides is affected by their molecular charges 33, 34 . As the renal brush border membrane is negatively charged, a repulsive force could arise between this membrane and negatively charged compounds. Such repulsive force could inhibit the reabsorption of these compounds into renal proximal tubular cells. The introduction of negative charges into radiometal-labeled peptides has also been studied to develop a method of decreasing the accumulation of radioactivity in the kidneys 35 . The extremely low accumulation of radioactivity in the kidneys after the injection of 67 Ga-DOTA-(L-Asp) 14 and 67 Ga-DOTA-(D-Asp) 14 may have been caused by their negative charges. We had expected that 67 Ga-DOTA-(L-Glu) 14 and 67 Ga-DOTA-(D-Glu) 14 , being negatively charged like 67 Ga-DOTA-(L-Asp) 14 and 67 Ga-DOTA-(D-Asp) 14 , would also cause low accumulation of radioactivity in the kidneys. However, contrary to our expectations, high accumulation and retention or slower clearance of radioactivity in the kidneys were observed after the injection of 67 Ga-DOTA-(L-Glu) 14 or 67 Ga-DOTA-(D-Glu) 14 . The mechanism behind these phenomena are unclear, but we must conclude that the glutamic acid peptides are not appropriate as carriers to the bone in the nuclear medicine imaging because of their association with high radioactivity in the kidneys.
In this study, no differences in the biodistributions between L-aspartic acid [ 67 Ga-DOTA-(L-Asp) n ] and D-aspartic acid [ 67 Ga-DOTA-(D-Asp) n ] compounds were observed, presumably because of their extremely rapid blood clearance. Recently, we have proposed a new concept of using a bifunctional peptide containing an aspartic acid peptide linker as a carrier to bone metastases and an RGD peptide, which has high affinity for α v β 3 integrin, as a carrier to primary cancer 31 . In this compound, L-aspartic acid is used as a composite component of the aspartic acid peptide linker. A D-aspartic acid peptide linker may be effective in the new approach. Higher stability of the D-aspartic acid peptide linker should be effective for higher accumulation in target tissues because the blood clearance of bifunctional peptide does not occur as rapidly as that of 67 Ga-DOTA-(D-Asp) n . Further studies are needed to examine the effectiveness of a D-aspartic acid peptide linker in the drug design concept. Asp) n (n = 2, 5, 8, 11, or 14) . The protected peptidyl resin was manually constructed by an Fmoc-based solid-phase methodology using a method described previously 19 . After the construction of the peptide chain on the resin, the Fmoc protecting group was removed using 20% piperidine in dimethylformamide (DMF), and a mixture containing two equivalents of DOTA-tris, 1,3-diisopropylcarbodiimide (DIPCDI), and 1-hydroxybenzotriazole hydrate (HOBt) in dimethylformamide (DMF) was added and allowed to react for 2 h. For the cleavage of peptides from the resin and deprotection, 0.5 mL of thioanisole and 5 mL of trifluoroacetic acid (TFA) were added to the completely protected peptide resin at 0 °C. After stirring at room temperature for 2 h, the resin was removed by filtration, and ether was added to the filtrate at 0 °C to precipitate crude peptide. The crude products were purified by reversed-phase (RP)-HPLC using a Hydrosphere 5C18 column (10 × 150 mm; YMC, Kyoto, Japan) at a flow rate of 4 mL/min with an isocratic mobile phase of water containing 0.1% TFA [in the case of DOTA-(D-Asp) 2 ] or using a Cosmosil 5C 18 
Synthesis of DOTA-(D-

